PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study

Plasma proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes

“…Because type 2 diabetes itself is strongly associated with chronic low‐level inflammation, the association between inflammation and PCSK9 may be different in non‐diabetic and diabetic populations, and further studies are warranted to analyse possible interactions. This is of particular relevance since several studies have shown a positive relationship between hsCRP and PCSK9 plasma levels . Other possible explanations for the effect of PCSK9 on CVD involve its impact on atherogenic lipoproteins independently of its impact on the LDLR pathway.…”

“…The association between CVD and circulating PCSK9 levels has been evaluated in the community and/or healthy populations, 9,11,13 in patients with acute coronary syndrome 10 or stable coronary artery disease, 34,35 in patients with acute coronary syndrome or stable angina 36 and in patients with chronic kidney disease. 12 Vlachopoulos et al 14 41,42 In addition, statins are more likely to be prescribed in patients with the highest risk of developing CVD.…”

“…This is of particular relevance since several studies have shown a positive relationship between hsCRP and PCSK9 plasma levels. [9][10][11][12][13][34][35][36] Other possible explanations for the effect of PCSK9 on CVD involve its impact on atherogenic lipoproteins independently of its impact on the LDLR pathway. Guardiola et al 16 recently reported that circulating PCSK9 levels were positively correlated with large very-low-density lipoprotein and their remnants, intermediate-density…”

PCSK9 and Atherosclerosis - Lipids and Beyond

“…Cheng et al utilized a novel approach to see if they could recapitulate experimental findings regarding PCSK9-induced inflammation and atherosclerosis by employing intravascular ultrasound virtual histology (IVUS-VH) as a tool in humans 72) . They evaluated the association of serum PCSK9 levels with necrotic core within coronary atherosclerotic lesions in subjects with known CAD confirmed at the time of angiography.…”

Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors

“…Similarly, cohort studies have revealed variable associations between PCSK9 levels and cardiovascular event rates in primary prevention populations . PCSK9 levels have been shown with intravascular ultrasound to have a linear association with necrotic core fraction and volume but not with total plaque burden …”